NO2864328T3 - - Google Patents

Info

Publication number
NO2864328T3
NO2864328T3 NO13731470A NO13731470A NO2864328T3 NO 2864328 T3 NO2864328 T3 NO 2864328T3 NO 13731470 A NO13731470 A NO 13731470A NO 13731470 A NO13731470 A NO 13731470A NO 2864328 T3 NO2864328 T3 NO 2864328T3
Authority
NO
Norway
Application number
NO13731470A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2864328T3 publication Critical patent/NO2864328T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO13731470A 2012-06-21 2013-06-21 NO2864328T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1211021.9A GB201211021D0 (en) 2012-06-21 2012-06-21 Pharmaceutically active compounds
PCT/GB2013/051633 WO2013190319A1 (en) 2012-06-21 2013-06-21 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
NO2864328T3 true NO2864328T3 (cg-RX-API-DMAC10.html) 2018-05-05

Family

ID=46641296

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13731470A NO2864328T3 (cg-RX-API-DMAC10.html) 2012-06-21 2013-06-21

Country Status (23)

Country Link
US (1) US9447092B2 (cg-RX-API-DMAC10.html)
EP (1) EP2864328B8 (cg-RX-API-DMAC10.html)
JP (1) JP6159397B2 (cg-RX-API-DMAC10.html)
CN (1) CN104470922B (cg-RX-API-DMAC10.html)
AU (1) AU2013279040B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014032142B1 (cg-RX-API-DMAC10.html)
CA (1) CA2876357C (cg-RX-API-DMAC10.html)
CY (1) CY1120608T1 (cg-RX-API-DMAC10.html)
DK (1) DK2864328T3 (cg-RX-API-DMAC10.html)
ES (1) ES2660159T3 (cg-RX-API-DMAC10.html)
GB (1) GB201211021D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20180386T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036048T2 (cg-RX-API-DMAC10.html)
IN (1) IN2015MN00045A (cg-RX-API-DMAC10.html)
LT (1) LT2864328T (cg-RX-API-DMAC10.html)
NO (1) NO2864328T3 (cg-RX-API-DMAC10.html)
PL (1) PL2864328T3 (cg-RX-API-DMAC10.html)
PT (1) PT2864328T (cg-RX-API-DMAC10.html)
RS (1) RS56996B1 (cg-RX-API-DMAC10.html)
RU (1) RU2654942C2 (cg-RX-API-DMAC10.html)
SI (1) SI2864328T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800128T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013190319A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Hp1の機能に着目した抗癌剤のスクリーニング方法及び評価系
GB2596038B (en) * 2020-03-04 2022-12-14 Ellipses Pharma Ltd Salts and polymorphic forms of (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-B]pyridine)
GB2592622B (en) * 2020-03-04 2022-08-03 Ellipses Pharma Ltd Formulations of a dual aurora kinase/FLT3 inhibitor
WO2026017996A1 (en) 2024-07-16 2026-01-22 Ellipses Pharma Ltd Combinations of cct241736 and venetoclax, or of cct241736, venetoclax and azacitidine for use in the treatment of cancer
WO2026020051A1 (en) * 2024-07-19 2026-01-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading aurora kinase via ubiquitin proteosome pathway

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP1963315B1 (en) * 2005-12-22 2014-10-08 Cancer Research Technology Limited Enzyme inhibitors
CN101616920A (zh) * 2007-01-30 2009-12-30 比奥根艾迪克Ma公司 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途
WO2009001021A1 (en) 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
CA2728559A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
EP2616469B1 (en) * 2010-09-14 2016-10-26 Exelixis, Inc. 9h-purine compounds as pi3k-delta inhibitors and methods for their manufacture

Also Published As

Publication number Publication date
JP6159397B2 (ja) 2017-07-05
JP2015520222A (ja) 2015-07-16
GB201211021D0 (en) 2012-08-01
WO2013190319A1 (en) 2013-12-27
ES2660159T3 (es) 2018-03-21
US9447092B2 (en) 2016-09-20
CY1120608T1 (el) 2019-12-11
HUE036048T2 (hu) 2018-06-28
AU2013279040A1 (en) 2015-01-29
BR112014032142B1 (pt) 2022-03-03
LT2864328T (lt) 2018-04-10
BR112014032142A2 (pt) 2017-06-27
HRP20180386T1 (hr) 2018-04-20
RS56996B1 (sr) 2018-05-31
AU2013279040B2 (en) 2017-11-16
RU2015101702A (ru) 2016-08-10
CA2876357C (en) 2020-07-14
PT2864328T (pt) 2018-03-12
IN2015MN00045A (cg-RX-API-DMAC10.html) 2015-10-16
EP2864328B8 (en) 2018-01-24
CN104470922A (zh) 2015-03-25
PL2864328T3 (pl) 2018-06-29
SMT201800128T1 (it) 2018-05-02
CN104470922B (zh) 2016-08-24
CA2876357A1 (en) 2013-12-27
RU2654942C2 (ru) 2018-05-25
EP2864328B1 (en) 2017-12-06
DK2864328T3 (en) 2018-03-12
EP2864328A1 (en) 2015-04-29
US20150266868A1 (en) 2015-09-24
SI2864328T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017607A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017646A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
AR092201A1 (cg-RX-API-DMAC10.html)
BR112014024270A2 (cg-RX-API-DMAC10.html)
BR112013027865A2 (cg-RX-API-DMAC10.html)
BR112014019605A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014017634A2 (cg-RX-API-DMAC10.html)
BR112014017588A2 (cg-RX-API-DMAC10.html)
BR112014017647A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017618A2 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017623A2 (cg-RX-API-DMAC10.html)
BR112014017652A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017621A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014017622A2 (cg-RX-API-DMAC10.html)
BR112014017671A2 (cg-RX-API-DMAC10.html)
BR112014017589A2 (cg-RX-API-DMAC10.html)